P/E - VistaGen Therapeutics Inc (NASDAQ:VTGN) - Alpha Spread
V

VistaGen Therapeutics Inc
NASDAQ:VTGN

Watchlist Manager
VistaGen Therapeutics Inc
NASDAQ:VTGN
Watchlist
Price: 3 USD Market Closed
Market Cap: 81.2m USD
Have any thoughts about
VistaGen Therapeutics Inc?
Write Note

P/E
Price to Earnings

-2.4
Current
-2.8
Median
23.9
Industry
Higher than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-2.4
=
Market Cap
81.2m USD
/
Net Income
-33.2m USD
All Countries
Close
Earnings Growth
US
V
VistaGen Therapeutics Inc
NASDAQ:VTGN
Average P/E: 57.5
Negative Multiple: -2.4
N/A
US
Abbvie Inc
NYSE:ABBV
64.6
406%
US
Amgen Inc
NASDAQ:AMGN
57.7
74%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
29.6
56%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -251.7
38%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -505.7 N/A
US
Gilead Sciences Inc
NASDAQ:GILD
99.3
71%
AU
CSL Ltd
ASX:CSL
36.6
64%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.5 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 169.6 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -485.3 N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
-1.7
2-Years Forward
P/E
-1.7
3-Years Forward
P/E
-1.6

See Also

Discover More